thalidomide has been researched along with Island Cell Tumor in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses." | 2.73 | Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. ( Campbell, J; Shah, MH; Varker, KA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varker, KA | 1 |
| Campbell, J | 1 |
| Shah, MH | 1 |
1 trial available for thalidomide and Island Cell Tumor
| Article | Year |
|---|---|
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoid Tumor; Chrom | 2008 |